Liliana Michelle Gomez Mendez, Matthew D. Cascino, Jay Garg, Tamiko R. Katsumoto, Paul Brakeman, Maria Dall’Era, Richard John Looney, Brad Rovin, Leonard Dragone, Paul Brunetta: Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clin J Am Soc Nephrol 13: 1502–1509; published ahead of print August 8, 2018, doi: 10.2215/CJN.01070118.
Due to author error, the Clinicatrials.gov identifier was incorrectly listed in the article as indicated below. The correct trial number identifier is NCT02550652.
“The NOBILITY study is an ongoing phase II trial in subjects with proliferative lupus nephritis randomized to either obinutuzumab or placebo plus background therapy of mycophenolate and steroids (clinicaltrials.gov identifier NCT01905943) that aims to test the hypothesis that greater B-cell depletion can lead to increased rates of response in subjects with lupus nephritis.”
Footnotes
Published online ahead of print. Publication date available at www.cjasn.org.
- Copyright © 2019 by the American Society of Nephrology
In this issue
Jump to section
Recent Tweets about the Article
-
RT @ScienceMagazine: Researchers introduce “sci-Space,” a new method for embryo-scale, single-cell spatial transcriptomics. They used the…
-
RT @ScienceMagazine: Researchers introduce “sci-Space,” a new method for embryo-scale, single-cell spatial transcriptomics. They used the…
More in this TOC Section
Cited By...
- No citing articles found.